Hypophosphatasia (HPP) is the inborn-error-of-metabolism that features rickets or osteomalacia due to loss-of-function mutation within the tissue-nonspecific alkaline phosphatase (TNAP) gene. To-date, there is no established medical treatment for this condition. Our work has clearly shown that TNAP knockout mice (Akp2-/- mice) faithfully mimic the severe infantile form of HPP, and that their rickets/osteomalacia is caused by accumulation of extracellular levels of inorganic pyrophosphate (ePPi), one of TNAP's natural substrates and a potent calcification inhibitor. In turn, high ePPi leads to a secondary elevation of skeletal osteopontin (OPN), which functions as another potent calcification inhibitor. In turn, overexpression of TNAP in skeletal tissues leads to increases in bone mineral density and bone volume fraction, via a mechanism that involves reduction in ePPi levels and increased dephosphorylation of skeletal OPN. Epileptic seizures lead to the early demise of Akp2-/- mice and are caused by inadequate utilization of pyridoxal-5'-phosphate (PLP - a hydrophilic form of Vitamin B6), another natural substrate of TNAP. In a major breakthrough during this last funding period, we have shown that enzyme replacement therapy (EzRT) using a bone-targeted form of TNAP is able to completely prevent all the symptoms of HPP in the Akp2-/- mice, including the epileptic seizures and the severe skeletal and dental abnormalities characteristic of this excellent model of infantile HPP. Our findings represent the first successful use of EzRT for a heritable primary disease of the skeleton, and are a foundation for future therapeutic trials for human HPP. With that ultimate goal in mind, the present competitive renewal application focuses sharply on optimizing this EzRT strategy in TNAP-deficient mouse models.
Our Specific Aims are: I) To test the hypothesis that EzRT not only prevents HPP in Akp2-/- mice but can also rescue Akp2-/- mice with advanced HPP disease. Additionally, we will compare the relative efficacy of administering bone-targeted versus soluble TNAP in Akp2-/- mice. II) To test the hypothesis that EzRT will also be efficacious to prevent and treat "adult HPP". We will compare the phenotypic abnormalities of three different mouse strains, i.e., a bone-specific TNAP knockout model (Akp2flox/flox;Col1a1-Cre), a transgenic model of dominant HPP (Col1a1- TnapD361V) and a ENU-mutagenesis model of semi-dominant HPP (Akp2Hpp/Hpp) and evaluate the efficacy of EzRT on the most representative model. III) To test the hypothesis that pharmacological "activators" of TNAP's pyrophosphatase activity can be used to stimulate bone mineralization in vitro and in vivo. We will also assess the ability of these TNAP activators to stimulate in vitro the residual TNAP activity present in serum samples from genotyped HPP patients to identify what TNAP mutations might respond to such a pharmacological intervention. Our work will have an immediate impact on the clinical management of HPP patients, while providing further insights into the pathogenesis of this variable disease. The novel TNAP activators that we have discovered may prove of interest for the prevention and treatment of osteoporosis.
Our studies have shown that sustained delivery of bone-targeted alkaline phosphatase can prevent the sequelae of the heritable form of rickets and osteomalacia known as hypophosphatasia, recapitulated in Akp2-/- mice. These observations represent the first demonstration of successful enzyme replacement therapy to prevent a primary skeletal disease of genetic origin in a mouse model, and are a foundation for clinical trials in patients suffering from this inborn-error-of-metabolism. The work in this application will optimize the use of enzyme replacement therapy to treat the most severe as well as the milder forms of the disease in diverse mouse models. These studies will be followed immediately by clinical trials in human hypophosphatasia patients. In addition, we have uncovered novel activators of alkaline phosphatase function that can be developed into pharmaceuticals to increase bone mineral density in patients with hypophosphatasia and osteoporosis.
|MillÃ¡n, JosÃ© Luis; Whyte, Michael P (2016) Alkaline Phosphatase and Hypophosphatasia. Calcif Tissue Int 98:398-416|
|Chaudhary, Sandeep C; Kuzynski, Maria; Bottini, Massimo et al. (2016) Phosphate induces formation of matrix vesicles during odontoblast-initiated mineralization in vitro. Matrix Biol 52-54:284-300|
|Liu, Jin; Campbell, Cassie; Nam, Hwa Kyung et al. (2015) Enzyme replacement for craniofacial skeletal defects and craniosynostosis in murine hypophosphatasia. Bone 78:203-11|
|Garcia, A F; SimÃ£o, A M S; Bolean, M et al. (2015) Effects of GPI-anchored TNAP on the dynamic structure of model membranes. Phys Chem Chem Phys 17:26295-301|
|Bolean, MaytÃª; SimÃ£o, Ana Maria S; Kiffer-Moreira, Tina et al. (2015) Proteoliposomes with the ability to transport Ca(2+) into the vesicles and hydrolyze phosphosubstrates on their surface. Arch Biochem Biophys 584:79-89|
|Zweifler, Laura E; Patel, Mudita K; Nociti Jr, Francisco H et al. (2015) Counter-regulatory phosphatases TNAP and NPP1 temporally regulate tooth root cementogenesis. Int J Oral Sci 7:27-41|
|Gasque, Kellen C S; Foster, Brian L; Kuss, Pia et al. (2015) Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl-/- mice by administration of soluble (non-targeted) chimeric alkaline phosphatase. Bone 72:137-47|
|Foster, B L; Sheen, C R; Hatch, N E et al. (2015) Periodontal Defects in the A116T Knock-in Murine Model of Odontohypophosphatasia. J Dent Res 94:706-14|
|Sheen, Campbell R; Kuss, Pia; Narisawa, Sonoko et al. (2015) Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification. J Bone Miner Res 30:824-36|
|Savinov, Alexei Y; Salehi, Maryam; Yadav, Manisha C et al. (2015) Transgenic Overexpression of Tissue-Nonspecific Alkaline Phosphatase (TNAP) in Vascular Endothelium Results in Generalized Arterial Calcification. J Am Heart Assoc 4:|
Showing the most recent 10 out of 83 publications